Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
University of Louisville
Study ID
NCT00290407
Phase
PHASE2
Status
Terminated

Conditions

  • Leukemia, Lymphocytic, Chronic
  • Lymphoma, Small Lymphocytic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    375 mg/m2, IV (in the vein), once a week for 4 weeks
  • Beta-Glucan — DIETARY_SUPPLEMENT
    250 mg, orally (tablet), three times a day for 9 weeks

Study Details

The purpose of this study is to determine how well subjects respond to treatment with Rituximab plus Beta-Glucan.

Key Dates

Start date
Mar 31, 2006
Status verified
Apr 2018
Primary completion
Jan 31, 2010
Completion
Jan 31, 2010

Study Design

Enrollment
2 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

CT Scan to Measure Clinical Effect (Response) [ Time Frame: 3 months after starting treatment, 6 months after starting treatment, and every 6 months (after completing treatment) until disease progression ]

Locations (1)

FacilityCityStateZIPSite coordinators
James Graham Brown Cancer CenterLouisvilleKentucky40202-

Find similar trials in Louisville, KY

By research site
James Graham Brown Cancer Center· Louisville, KY

Related Studies